Clozapine Eligibility in a Patient with Active or Recent Substance Use
He clearly meets the clinical threshold for clozapine, but ongoing cannabis and intermittent stimulant use complicate both monitoring reliability and interaction risk. Excluding him isn't obviously right, and neither is proceeding as if the use isn't there.
N.D., a 26-year-old man, works part-time doing freelance graphic design from home, a job he found precisely because it accommodates the unpredictability of his illness in a way an on-site position never could. He has failed two adequate antipsychotic trials over a four-year illness course and continues to have significant positive symptoms, meeting standard criteria for treatment-resistant schizophrenia. He also has ongoing daily cannabis use and intermittent stimulant use, which he acknowledges openly and says he isn't ready to stop, though he has never missed a scheduled clinic appointment in the two years his current care team has followed him.
He lives alone in a rented room and says the design work, however inconsistent, is the one part of his life that has stayed genuinely his despite everything else the illness has taken — a detail his care team has come to see as relevant context, not incidental, when weighing how reliably he might manage a demanding new monitoring schedule.
Neither active substance use nor stimulant use is an absolute contraindication to clozapine, but both raise genuine, specific concerns: reliable attendance for weekly blood draws is essential to safe clozapine monitoring, and a pattern of substance use severe enough to threaten that reliability would be a real safety problem, not just a moral judgment about the use itself. Stimulant use in particular raises legitimate concern about cardiovascular strain when combined with clozapine's own effects, and heavy cannabis use is a known factor affecting CYP1A2 activity, the enzyme largely responsible for clozapine metabolism, which can meaningfully shift clozapine levels if use patterns change during treatment. N.D.'s actual attendance record over two years is a real, directly relevant data point that a blanket policy based on substance use status alone would miss entirely.
Clozapine eligibility given ongoing use
His attendance record over two years is real evidence, not a hypothetical — the actual concern with substance use and clozapine monitoring is reliability, and he's demonstrated exactly that reliability consistently. I wouldn't treat active cannabis and stimulant use as an automatic exclusion when the specific behavior it's meant to predict hasn't shown up.
I agree on eligibility, and I want to flag something more specific than a general CYP1A2 caution. Caicedo and colleagues' 2025 pharmacokinetic review documents cannabis cessation specifically raising clozapine plasma levels by roughly fifty percent within two to four weeks, and describes case reports with increases well above that — over double, in one published case — when cannabis and tobacco cessation happen together, severe enough to cause hallucinations from the elevated level itself. His attendance record tells us he'll show up for a blood draw. It doesn't tell us his use pattern will stay constant. If it changes in either direction once he's on this drug, that's a real clinical event, not background noise, and it needs a plan attached to it now, before it happens.
Both of you have made the eligibility and monitoring case well, and I'm not reopening either. But I'd hold one separate piece open a bit longer: the stimulant use is a distinct mechanism from the CYP1A2 question, not another version of it, and I'd want it addressed before, not after, initiation. A baseline ECG and an honest conversation with him about the added cardiovascular strain of combining clozapine with stimulant use is reasonable due diligence, not gatekeeping layered onto a question the two of you have already settled.
Agreed: proceed with clozapine initiation, with baseline ECG completed first and N.D.'s substance use pattern tracked explicitly at each monitoring visit as a factor in interpreting both his clozapine level and his cardiovascular status, not managed separately from his psychiatric care.
N.D. was told directly that his honesty about ongoing use, rather than being held against him, is exactly what made a more individualized eligibility decision possible — a distinction the addiction specialist felt was worth naming so he has no reason to hide use patterns that are clinically relevant to track.